Bone morphogenetic protein 10 (BMP10) is a protein encoded by the BMP10 gene in humans. BMP10 is a polypeptide that belongs to the TGF-beta superfamily of proteins. It is a novel protein that, unlike most other BMPs, may be involved in trabecular formation in the heart. Bone morphogenetic proteins are known for their ability to induce bone and cartilage development. BMP10 is classified as a BMP because of its large sequence homology with other BMPs in the TGF-β superfamily. CD ComputaBio now offers professional BMP-10 targeting services to meet your research needs.
A prerequisite for reverse docking is a collection of target structures containing information about potential ligand-binding regions. The correct construction of the target structure database is a key step to improve the accuracy and applicability of the reverse docking method. Our researchers selected specific reverse docking tools and servers to meet specific conditions and purposes. Many studies have used reverse docking as a primary method or as a secondary option for the analysis of broad-spectrum targets associated with small molecules.
CD ComputaBio provides comprehensive and high-quality biological data analysis services, our team of experts creates an efficient data analysis platform that can perform the required analysis for a client's specific technical or biological research question. Our goal is to enable researchers to make meaningful observations and discoveries from the vast amounts of data analyzed by the target.
Scientists at CD ComputaBio can use project data or published data to build QSAR and other models to predict ADMET properties of new compounds. We are experienced in supporting multi-parameter optimization during the design process. We can also estimate these properties using ADMET QSAR models built by software vendors.
CD ComputaBio provides corresponding BMP-10 targeting services. Our computational services provide accurate approximations of real molecular behavior and have proven useful for understanding the biochemical basis of physiological events at different stages of drug development. Our team of experts can provide up to a millisecond of simulation time for the system of your choice, so you don't have to worry about technical issues.
De novo drug design technology is a drug molecule design method based on the three-dimensional structure of receptors. The technology analyzes the active site of the target molecule and constructs a drug molecule that matches the active site. The advantage of de novo design technology is to provide new ideas for new drug research and development, make full use of the structural information of known compounds, avoid waste of research and development resources to a certain extent, and speed up the development of new drugs. It has strong feasibility and broad development prospects, and may become an important tool for new drug research and development. Our de novo design service steps mainly include:
Analyze the active site of the target to determine the distribution of active sites, potential fields, and key functional residues.
Use different strategies to place basic building blocks into active sites and generate complete new molecules.
Binding energies of new molecules and receptor molecules are calculated to predict biological activity.